Intervallet for peak steady- state plasmakoncentrationer for olopatadin (35 til 127 ng/ ml) set i dette forsøg svarer til mindst 70 gange sikkerhedsmargin for topikal olopatadin med hensyn til virkning på hjertets repolarisering.
The range of peak steady-state olopatadine plasma concentrations (35 to 127 ng/ ml) seen in this study represents at least a 70-fold safety margin for topical olopatadine with respect to effects on cardiac repolarisation.